Nervonik Announces $52.5 Million Series B Financing to Advance Peripheral Nerve Stimulation Therapy

Nervonik, Inc., a clinical-stage medical device company developing next-generation peripheral nerve stimulation (PNS) technologies, today announced the closing of an oversubscribed $52.5 million Series B financing.